Human Milk Fortification in Extremely Preterm Infants
Key facts
- Who runs it
- Thomas Abrahamsson, MD, PhD
- Where
- Sweden5 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2/3
- People taking part
- 229 people enrolled
- Started
- 1 Feb 2019
- Expected to end
- 31 Jan 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- H2MF
- Bovine milk-based fortifier
- Record updated
- 23 July 2024
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Gestational age at birth 22+0-27+6: based on prenatal ultrasonography
- Enteral feeds < 100 mL/kg/day at the day of randomisation
- Written informed consent from the legal guardians of the infant
- The home clinic of the infant has the logistics of maintaining the intervention until gestational week 34+0
Who cannot take part
- Abdominal surgery before the time of inclusion
- Infants having nutrient fortifier or formula prior to randomisation
- Lethal or complicated malformation known at the time of inclusion
- Chromosomal anomalies known at the time of inclusion
- No realistic hope for survival at the time of inclusion
- Gastrointestinal malformation known at the time of inclusion
- Participation in another intervention trial aiming at having an effect on growth, nutrition, feeding intolerance or severe complications such as NEC and sepsis
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a randomised controlled multi-centre trial comparing the effect of diet supplementation of a human breast milk-based nutrient fortifier (H2MF®) with standard bovine protein-based nutrient fortifier in 222 extremely preterm infants (born before gestational week 28+0) exclusively fed with human breast milk (own mother´s milk and/or donor milk). The infants will be randomised to receive either the human breast-milk based H2MF® or the standard bovine protein-based nutrient fortifier when oral feeds have reached <100 ml/kg/day.
Read full original descriptionShow less
The randomised intervention, stratified by centre, will continue until the target gestational week 34+0. The infant must not be fed with formula during the intervention period. The allocation will be concealed before inclusion, but after randomisation the study is not blinded.
Primary endpoint of the intervention is the composite variable necrotizing enterocolitis (NEC), sepsis and mortality.
The enrolled infants are characterised with clinical data including growth, feeding intolerance, use of enteral and parenteral nutrition, treatment, antibiotics and complications collected daily in a study specific case report form from birth until discharge from the hospital (not longer than gestational week 44+0). A follow up focusing on neurological development, growth and feeding problems will be performed at 2 years of age (corrected) and 5.5 years of age.
The 2 groups in the trial
- H2MFTreatment being tested
Human milk-based breast milk fortifier
- Standard fortifierExisting treatment, for comparison
Standard care: bovine milk-based breast milk fortifier
Treatment: Bovine milk-based fortifier
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Nordic Study on Human Milk Fortification in Extremely Preterm Infants: a Randomized Controlled Trial
- Publications
- Record updated
- 23 July 2024